Niagen Bioscience Director Receives 20,000 Stock Options at $14.13 Strike Price

Director Gary Ng Wang Yu of Niagen Bioscience (NAGE) was granted stock options on June 24, 2025.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Director Gary Ng Wang Yu of Niagen Bioscience (NAGE) was granted stock options on June 24, 2025. The key details of this Form 4 filing include:

Received 20,000 stock options to purchase common stock
Exercise price set at $14.13 per share
Options will vest 100% on June 24, 2026
Options expire on June 23, 2035
Transaction reported as a direct ownership

This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule suggests a standard annual director equity award structure. The 10-year exercise period from the grant date provides long-term alignment with shareholder interests.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Ng Wang Yu Gary

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 20,000 contracts (Direct)

Footnotes (1)

F1. Option vests 100% on June 24, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did NAGE director Gary Ng Wang Yu receive on June 24, 2025?

NAGE director Gary Ng Wang Yu received 20,000 stock options with an exercise price of $14.13. These options were granted on June 24, 2025, and will vest 100% on June 24, 2026. The options have an expiration date of June 23, 2035.

When do the new NAGE stock options granted to Gary Ng Wang Yu vest?

The stock options granted to Gary Ng Wang Yu will vest 100% on June 24, 2026, which is a one-year cliff vesting schedule from the grant date.

What is the exercise price of NAGE stock options granted in June 2025?

The stock options granted by NAGE on June 24, 2025, have an exercise price of $14.13 per share.

How long does Gary Ng Wang Yu have to exercise his NAGE stock options?

Gary Ng Wang Yu's stock options have a 10-year exercise period, with an expiration date of June 23, 2035.

What position does Gary Ng Wang Yu hold at NAGE?

According to the Form 4 filing, Gary Ng Wang Yu serves as a Director of Niagen Bioscience, Inc. (NAGE).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/25/2025 - 08:28 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng Wang Yu Gary

(Last)

(First)

(Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES

90024

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$14.13	06/24/2025		A		20,000		06/24/2026⁽¹⁾	06/23/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Option vests 100% on June 24, 2026.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR